JP2022522112A - ヒト化細胞系 - Google Patents
ヒト化細胞系 Download PDFInfo
- Publication number
- JP2022522112A JP2022522112A JP2021546853A JP2021546853A JP2022522112A JP 2022522112 A JP2022522112 A JP 2022522112A JP 2021546853 A JP2021546853 A JP 2021546853A JP 2021546853 A JP2021546853 A JP 2021546853A JP 2022522112 A JP2022522112 A JP 2022522112A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- gene
- st3gal
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 144
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 82
- 241000700605 Viruses Species 0.000 claims abstract description 75
- 206010022000 influenza Diseases 0.000 claims abstract description 30
- 241000271566 Aves Species 0.000 claims abstract description 29
- 238000002955 isolation Methods 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 423
- 108010057005 beta-galactoside alpha-2,3-sialyltransferase Proteins 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 72
- 230000014509 gene expression Effects 0.000 claims description 68
- 150000007523 nucleic acids Chemical group 0.000 claims description 62
- 108091033409 CRISPR Proteins 0.000 claims description 44
- 108090000141 Sialyltransferases Proteins 0.000 claims description 39
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 239000002773 nucleotide Substances 0.000 claims description 38
- 230000035772 mutation Effects 0.000 claims description 37
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 33
- 102000003838 Sialyltransferases Human genes 0.000 claims description 27
- 238000010354 CRISPR gene editing Methods 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 23
- 125000005630 sialyl group Chemical group 0.000 claims description 21
- 101150040526 ST3 gene Proteins 0.000 claims description 20
- 230000002829 reductive effect Effects 0.000 claims description 19
- 108010076477 haematoside synthetase Proteins 0.000 claims description 17
- 241000282465 Canis Species 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 13
- 101000863864 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 1 Proteins 0.000 claims description 12
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 12
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 101000863891 Homo sapiens Beta-galactoside alpha-2,6-sialyltransferase 2 Proteins 0.000 claims description 10
- 101710163270 Nuclease Proteins 0.000 claims description 9
- 102100029963 Beta-galactoside alpha-2,6-sialyltransferase 2 Human genes 0.000 claims description 8
- 102100029945 Beta-galactoside alpha-2,6-sialyltransferase 1 Human genes 0.000 claims description 7
- 101710136188 Beta-galactoside alpha-2,6-sialyltransferase 2 Proteins 0.000 claims description 7
- 108010064886 beta-D-galactoside alpha 2-6-sialyltransferase Proteins 0.000 claims description 7
- 230000002103 transcriptional effect Effects 0.000 claims description 7
- 241000713196 Influenza B virus Species 0.000 claims description 6
- 108700026244 Open Reading Frames Proteins 0.000 claims description 6
- 241000702437 Parvovirus H3 Species 0.000 claims description 6
- 241000831652 Salinivibrio sharmensis Species 0.000 claims description 6
- 238000010362 genome editing Methods 0.000 claims description 6
- 241000712431 Influenza A virus Species 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 5
- 239000012636 effector Substances 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000048059 human St6Gal2 Human genes 0.000 claims 2
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000012010 growth Effects 0.000 abstract description 7
- 230000000644 propagated effect Effects 0.000 abstract description 6
- 108010066342 Virus Receptors Proteins 0.000 abstract description 4
- 102000018265 Virus Receptors Human genes 0.000 abstract description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 69
- 102000004196 processed proteins & peptides Human genes 0.000 description 62
- 229920001184 polypeptide Polymers 0.000 description 59
- 108020004414 DNA Proteins 0.000 description 49
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 47
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 47
- 102000040430 polynucleotide Human genes 0.000 description 42
- 108091033319 polynucleotide Proteins 0.000 description 42
- 239000002157 polynucleotide Substances 0.000 description 42
- 102000039446 nucleic acids Human genes 0.000 description 40
- 108020004707 nucleic acids Proteins 0.000 description 40
- 235000018102 proteins Nutrition 0.000 description 38
- 239000000203 mixture Substances 0.000 description 36
- 101710154606 Hemagglutinin Proteins 0.000 description 35
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 35
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 35
- 101710176177 Protein A56 Proteins 0.000 description 35
- 239000000185 hemagglutinin Substances 0.000 description 35
- 150000001413 amino acids Chemical class 0.000 description 31
- 108010006232 Neuraminidase Proteins 0.000 description 29
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 28
- 101150055766 cat gene Proteins 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 27
- 239000013598 vector Substances 0.000 description 27
- 102000005348 Neuraminidase Human genes 0.000 description 26
- 239000000047 product Substances 0.000 description 19
- 108090001090 Lectins Proteins 0.000 description 18
- 102000004856 Lectins Human genes 0.000 description 18
- 108020004511 Recombinant DNA Proteins 0.000 description 18
- 230000027455 binding Effects 0.000 description 18
- 239000002523 lectin Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- 238000003556 assay Methods 0.000 description 16
- 238000012546 transfer Methods 0.000 description 16
- 108020005004 Guide RNA Proteins 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 241000894007 species Species 0.000 description 15
- 108091026890 Coding region Proteins 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 230000000295 complement effect Effects 0.000 description 13
- 230000000120 cytopathologic effect Effects 0.000 description 13
- 108700019146 Transgenes Proteins 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 108091028113 Trans-activating crRNA Proteins 0.000 description 11
- 238000009395 breeding Methods 0.000 description 11
- 230000001488 breeding effect Effects 0.000 description 11
- 238000012239 gene modification Methods 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 239000013603 viral vector Substances 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 11
- 102100030928 Lactosylceramide alpha-2,3-sialyltransferase Human genes 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 230000005017 genetic modification Effects 0.000 description 10
- 235000013617 genetically modified food Nutrition 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 9
- 102100027098 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Human genes 0.000 description 9
- 229960001230 asparagine Drugs 0.000 description 9
- 235000009582 asparagine Nutrition 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 9
- 241000282472 Canis lupus familiaris Species 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 102000053359 human ST6GAL1 Human genes 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 102100027211 Albumin Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 102100029962 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Human genes 0.000 description 7
- 102100031974 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Human genes 0.000 description 7
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 102100027107 Type 2 lactosamine alpha-2,3-sialyltransferase Human genes 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 150000002482 oligosaccharides Polymers 0.000 description 7
- 238000003753 real-time PCR Methods 0.000 description 7
- 125000006850 spacer group Chemical group 0.000 description 7
- 102100031973 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical group NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Chemical group 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000001932 seasonal effect Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 108091027544 Subgenomic mRNA Proteins 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229930189065 blasticidin Natural products 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001476 gene delivery Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- 241001522306 Serinus serinus Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229960003971 influenza vaccine Drugs 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000007480 sanger sequencing Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 3
- 230000005030 transcription termination Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Chemical group 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100024125 Embryonal Fyn-associated substrate Human genes 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101001053896 Homo sapiens Embryonal Fyn-associated substrate Proteins 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 101710165105 Lactosylceramide alpha-2,3-sialyltransferase Proteins 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- 101150080862 NA gene Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical group OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 241000208829 Sambucus Species 0.000 description 2
- 235000018735 Sambucus canadensis Nutrition 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 108070000030 Viral receptors Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000010170 biological method Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 235000007123 blue elder Nutrition 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 235000007124 elderberry Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 235000008995 european elder Nutrition 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 229940027941 immunoglobulin g Drugs 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 208000037798 influenza B Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108010061514 sialic acid receptor Proteins 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- IXDZFGATLNCIOI-NGJCXOISSA-N (3r,4r,5r)-3,4,5,6-tetrahydroxyhexan-2-one Chemical group CC(=O)[C@H](O)[C@H](O)[C@H](O)CO IXDZFGATLNCIOI-NGJCXOISSA-N 0.000 description 1
- JABNPSKWVNCGMX-UHFFFAOYSA-N 2-(4-ethoxyphenyl)-6-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-benzimidazole;trihydrochloride Chemical compound Cl.Cl.Cl.C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 JABNPSKWVNCGMX-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- COCMHKNAGZHBDZ-UHFFFAOYSA-N 4-carboxy-3-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]benzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(C([O-])=O)=CC=C1C(O)=O COCMHKNAGZHBDZ-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 241000207208 Aquifex Species 0.000 description 1
- 241001167018 Aroa Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 1
- 101710136075 CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 101710083568 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 Proteins 0.000 description 1
- 101710083563 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2 Proteins 0.000 description 1
- 101710083574 CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 4 Proteins 0.000 description 1
- HOEWKBQADMRCLO-UIUGZIMDSA-N CMP-N-glycoloyl-beta-neuraminic acid Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)O[C@@]2(O[C@H]([C@H](NC(=O)CO)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)O1 HOEWKBQADMRCLO-UIUGZIMDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108091092236 Chimeric RNA Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 208000011038 Cold agglutinin disease Diseases 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100465553 Dictyostelium discoideum psmB6 gene Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 101100437498 Escherichia coli (strain K12) uidA gene Proteins 0.000 description 1
- 241001137858 Euryarchaeota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101150029965 HAT gene Proteins 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101100477543 Homo sapiens ST6GAL1 gene Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 241001521394 Maackia amurensis Species 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- KFEUJDWYNGMDBV-LODBTCKLSA-N N-acetyllactosamine Chemical group O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-LODBTCKLSA-N 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101100169519 Pyrococcus abyssi (strain GE5 / Orsay) dapAL gene Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 101150071661 SLC25A20 gene Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000005037 Sambucus racemosa Species 0.000 description 1
- 235000003139 Sambucus racemosa Nutrition 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 102220466467 Testis-specific H1 histone_D27N_mutation Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102220475290 Trichoplein keratin filament-binding protein_S44P_mutation Human genes 0.000 description 1
- 241000218989 Trichosanthes Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 101710204134 Type 2 lactosamine alpha-2,3-sialyltransferase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 101150037081 aroA gene Proteins 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- KFEUJDWYNGMDBV-RPHKZZMBSA-N beta-D-Galp-(1->4)-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KFEUJDWYNGMDBV-RPHKZZMBSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 101150102633 cact gene Proteins 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020345 childhood apraxia of speech Diseases 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 101150011371 dapA gene Proteins 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 150000008195 galaktosides Chemical class 0.000 description 1
- JGBUYEVOKHLFID-UHFFFAOYSA-N gelred Chemical compound [I-].[I-].C=1C(N)=CC=C(C2=CC=C(N)C=C2[N+]=2CCCCCC(=O)NCCCOCCOCCOCCCNC(=O)CCCCC[N+]=3C4=CC(N)=CC=C4C4=CC=C(N)C=C4C=3C=3C=CC=CC=3)C=1C=2C1=CC=CC=C1 JGBUYEVOKHLFID-UHFFFAOYSA-N 0.000 description 1
- 238000003197 gene knockdown Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000001295 genetical effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- MQUQNUAYKLCRME-UHFFFAOYSA-N n-(4-chloro-3-oxo-1-phenylbutan-2-yl)-4-methylbenzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102200127629 rs397514667 Human genes 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 208000014155 speech-language disorder-1 Diseases 0.000 description 1
- 101150019108 st6gal2 gene Proteins 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- -1 terminal α2 Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
- C12Y204/99001—Beta-galactoside alpha-2,6-sialyltransferase (2.4.99.1)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本出願は、2019年2月8日に出願されたアメリカ合衆国出願第62/803,266号の出願日の恩恵を主張するものであり、その開示内容は参照によって本明細書に組み込まれている。
本発明は、政府の援助を得て国立衛生研究所から資金提供されたHHSN272201400008Cのもとでなされた。政府は本発明において所定の権利を有する。
MIHTNLKKKFSCCVLVFLLFAVICVWKEKKKGSYYDSFKLQTKEFQVLKSLGKLAMGSDSQSVSSSSTQDPHRGRQTLGSLRGLAKAKPEASFQVWNKDSSSKNLIPRLQKIWKNYLSMNKYKVSYKGPGPGIKFSAEALRCHLRDHVNVSMVEVTDFPFNTSEWEGYLPKESIRTKAGPWGRCAVVSSAGSLKSSQLGREIDDHDAVLRFNGAPTANFQQDVGTKTTIRLMNSQLVTTEKRFLKDSLYNEGILIVWDPSVYHSDIPKWYQNPDYNFFNNYKTYRKLHPNQPFYILKPQMPWELWDILQEISPEEIQPNPPSSGMLGIIIMMTLCDQVDIYEFLPSKRKTDVCYYYQKFFDSACTMGAYHPLLYEKNLVKHLNQGTDEDIYLLGKATLPGFRTIHC(配列番号1)または
MIHTNLKKKFSCCVLVFLLFAVICVWKEKKKGSYYDSFKLQTKEFQVLKSLGKLAMGSDSQSVSSSSTQDPHRGRQTLGSLRGLAKAKPEASFQVWNKDSSSKNLIPRLQKIWKNYLSMNKYKVSYKGPGPGIKFSAEALRCHLRDHVNVSMVEVTDFPFNTSEWEGYLPKESIRTKAGPWGRCAVVSSAGSLKSSQLGREIDDHDAVLRFNGAPTANFQQDVGTKTTIRLMNSQLVTTEKRFLKDSLYNEGILIVWDPSVYHPDIPKWYQNPDYNFFNNYKTYRKLHPNQPFYILKPQMPWELWDILQEISPEEIQPNPPSSGMLGIIIMMTLCDQVDIYEFLPSKRRTDVCYYYQKFFDSACTMGAYHPLLFEKNLVKHLNQGTDEDIYLLGKATLPGFRTIHC(配列番号150)を含んでいて、
ATGATTCACACCAACCTGAAGAAAAAGTTCAGCTGCTGCGTCCTGGTCTTTCTTCTGTTTGCAGTCATCTGTGTGTGGAAGGAGAAGAAGAAAGGGAGTTACTATGATTCCTTTAAATTGCAAACCAAGGAATTCCAGGTGTTAAAGAGTCTGGGGAAATTGGCCATGGGGTCTGATTCCCAGTCTGTATCCTCAAGCAGCACCCAGGACCCCCACAGGGGCCGCCAGACCCTCGGCAGTCTCAGAGGCCTAGCCAAGGCCAAACCAGAGGCCTCCTTCCAGGTGTGGAACAAGGACAGCTCTTCCAAAAACCTTATCCCTAGGCTGCAAAAGATCTGGAAGAATTACCTAAGCATGAACAAGTACAAAGTGTCCTACAAGGGGCCAGGACCAGGCATCAAGTTCAGTGCAGAGGCCCTGCGCTGCCACCTCCGGGACCATGTGAATGTATCCATGGTAGAGGTCACAGATTTTCCCTTCAATACCTCTGAATGGGAGGGTTATCTGCCCAAGGAGAGCATTAGGACCAAGGCTGGGCCTTGGGGCAGGTGTGCTGTTGTGTCGTCAGCGGGATCTCTGAAGTCCTCCCAACTAGGCAGAGAAATCGATGATCATGACGCAGTCCTGAGGTTTAATGGGGCACCCACAGCCAACTTCCAACAAGATGTGGGCACAAAAACTACCATTCGCCTGATGAACTCTCAGTTGGTTACCACAGAGAAGCGCTTCCTCAAAGACAGTTTGTACAATGAAGGAATCCTAATTGTATGGGACCCATCTGTATACCACCCAGATATCCCAAAGTGGTACCAGAATCCGGATTATAATTTCTTTAACAACTACAAGACTTATCGTAAGCTGCACCCCAATCAGCCCTTTTACATCCTCAAGCCCCAGATGCCTTGGGAGCTATGGGACATTCTTCAAGAAATCTCCCCAGAAGAGATTCAGCCAAACCCCCCATCCTCTGGGATGCTTGGTATCATCATCATGATGACGCTGTGTGACCAGGTGGATATTTATGAGTTCCTCCCATCCAAGCGCAGGACTGACGTGTGCTACTACTACCAGAAGTTCTTCGATAGTGCCTGCACGATGGGTGCCTACCACCCGCTGCTCTTTGAGAAGAATTTGGTGAAGCATCTCAACCAGGGCACAGATGAGGACATCTACCTGCTTGGAAAAGCCACACTGCCTGGCTTCCGGACCATTCACTGCTAA(配列番号151)によってコードされているヒトST6(アクセッション番号KJ897554);
mkphlkqwrq rmlfgifawg llfllifiyf tdsnpaepvp sslsfletrr llpvqgkqra imgaahepsp pggldarqal prahpagsfh agpgdlqkwa qsqdgfehke ffssqvgrks qsafypeddd yffaagqpgw hshtqgtlgf pspgepgpre gafpaaqvqr rrvkkrhrrq rrshvleegd dgdrlyssms raflyrlwkg nvsskmlnpr lqkamkdylt ankhgvrfrg kreaglsraq llcqlrsrar vrtldgteap fsalgwrrlv pavplsqlhp rglrscavvm sagailnssl geeidshdav lrfnsaptrg yekdvgnktt iriinsqilt npshhfidss lykdvilvaw dpapysanln lwykkpdynl ftpyiqhrqr npnqpfyilh pkfiwqlwdi iqentkekiq pnppssgfig ilimmsmcre vhvyeyipsv rqtelchyhe lyydaactlg ayhpllyekl lvqrlnmgtq gdlhrkgkvv lpgfqavhcp apspviphs(配列番号2)を含むヒトST6(アクセッション番号BAC24793);
aamgsdsqsv sssstqdphr grqtlgslrg lakakpeasf qvwnkdsssk nliprlqkiw knylsmnkyk vsykgpgpgi kfsaealrch lrdhvnvsmv evtdfpfnts ewegylpkes irtkagpwgr cavvssagsl kssqlgreid dhdavlrfng aptanfqqdv gtkttirlmn sqlvttekrf lkdslynegi livwdpsvyh sdipkwyqnp dynffnnykt yrklhpnqpf yilkpqmpwe lwdilqeisp eeiqpnppss gmlgiiimmt lcdqvdiyef lpskrktdvc yyyqkffdsa ctmgayhpll yeknlvkhln qgtdediyll gkatlpgfrt ihc(配列番号3)を含むヒトST6(アクセッション番号SJL87798);または
ヒトST6 Gal-II
MKPHLKQWRQRMLFGIFAWGLLFLLIFIYFTDSNPAEPVPSSLSFLETRRLLPVQGKQRAIMGAAHEPSPPGGLDARQALPRAHPAGSFHAGPGDLQKWAQSQDGFEHKEFFSSQVGRKSQSAFYPEDDDYFFAAGQPGWHSHTQGTLGFPSPGEPGPREGAFPAAQVQRRRVKKRHRRQRRSHVLEEGDDGDRLYSSMSRAFLYRLWKGNVSSKMLNPRLQKAMKDYLTANKHGVRFRGKREAGLSRAQLLCQLRSRARVRTLDGTEAPFSALGWRRLVPAVPLSQLHPRGLRSCAVVMSAGAILNSSLGEEIDSHDAVLRFNSAPTRGYEKDVGNKTTIRIINSQILTNPSHHFIDSSLYKDVILVAWDPAPYSANLNLWYKKPDYNLFTPYIQHRQRNPNQPFYILHPKFIWQLWDIIQENTKEKIQPNPPSSGFIGILIMMSMCREVHVYEYIPSVRQTELCHYHELYYDAACTLGAYHPLLYEKLLVQRLNMGTQGDLHRKGKVVLPGFQAVHCPAPSPVIPHS(配列番号4);
ATGATTCACACCAACCTGAAGAAAAAGTTCAGCTGCTGCGTCCTGGTCTTTCTTCTGTTTGCAGTCATCTGTGTGTGGAAGGAGAAGAAGAAAGGGAGTTACTATGATTCCTTTAAATTGCAAACCAAGGAATTCCAGGTGTTAAAGAGTCTGGGGAAATTGGCCATGGGGTCTGATTCCCAGTCTGTATCCTCAAGCAGCACCCAGGACCCCCACAGGGGCCGCCAGACCCTCGGCAGTCTCAGAGGCCTAGCCAAGGCCAAACCAGAGGCCTCCTTCCAGGTGTGGAACAAGGACAGCTCTTCCAAAAACCTTATCCCTAGGCTGCAAAAGATCTGGAAGAATTACCTAAGCATGAACAAGTACAAAGTGTCCTACAAGGGGCCAGGACCAGGCATCAAGTTCAGTGCAGAGGCCCTGCGCTGCCACCTCCGGGACCATGTGAATGTATCCATGGTAGAGGTCACAGATTTTCCCTTCAATACCTCTGAATGGGAGGGTTATCTGCCCAAGGAGAGCATTAGGACCAAGGCTGGGCCTTGGGGCAGGTGTGCTGTTGTGTCGTCAGCGGGATCTCTGAAGTCCTCCCAACTAGGCAGAGAAATCGATGATCATGACGCAGTCCTGAGGTTTAATGGGGCACCCACAGCCAACTTCCAACAAGATGTGGGCACAAAAACTACCATTCGCCTGATGAACTCTCAGTTGGTTACCACAGAGAAGCGCTTCCTCAAAGACAGTTTGTACAATGAAGGAATCCTAATTGTATGGGACCCATCTGTATACCACCCAGATATCCCAAAGTGGTACCAGAATCCGGATTATAATTTCTTTAACAACTACAAGACTTATCGTAAGCTGCACCCCAATCAGCCCTTTTACATCCTCAAGCCCCAGATGCCTTGGGAGCTATGGGACATTCTTCAAGAAATCTCCCCAGAAGAGATTCAGCCAAACCCCCCATCCTCTGGGATGCTTGGTATCATCATCATGATGACGCTGTGTGACCAGGTGGATATTTATGAGTTCCTCCCATCCAAGCGCAGGACTGACGTGTGCTACTACTACCAGAAGTTCTTCGATAGTGCCTGCACGATGGGTGCCTACCACCCGCTGCTCTTTGAGAAGAATTTGGTGAAGCATCTCAACCAGGGCACAGATGAGGACATCTACCTGCTTGGAAAAGCCACACTGCCTGGCTTCCGGACCATTCACTGCTAA(配列番号100)によってコードされるヒトST6 Gal1;
MIHTNLKKKFSCCVLVFLLFAVICVWKEKKKGSYYDSFKLQTKEFQVLKSLGKLAMGSDSQSVSSSSTQDPHRGRQTLGSLRGLAKAKPEASFQVWNKDSSSKNLIPRLQKIWKNYLSMNKYKVSYKGPGPGIKFSAEALRCHLRDHVNVSMVEVTDFPFNTSEWEGYLPKESIRTKAGPWGRCAVVSSAGSLKSSQLGREIDDHDAVLRFNGAPTANFQQDVGTKTTIRLMNSQLVTTEKRFLKDSLYNEGILIVWDPSVYHPDIPKWYQNPDYNFFNNYKTYRKLHPNQPFYILKPQMPWELWDILQEISPEEIQPNPPSSGMLGIIIMMTLCDQVDIYEFLPSKRRTDVCYYYQKFFDSACTMGAYHPLLFEKNLVKHLNQGTDEDIYLLGKATLPGFRTIHC(配列番号101)を含むヒトST6 Gal1;
または配列番号1~4、101、または150のいずれか1つとアミノ酸配列が少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するタンパク質、または配列番号100または151のいずれか1つのヌクレオチド酸配列と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するヌクレオチド配列である。
gtcaggtctc agaaaagtct agaataaggc ttacaggcac tttgttcagt tgtggaacac atggaaactt catacaccgc ccccctcctt gcagaccgga gagctctctg ctctaatttg ggcacaggcg cccaaccttg ggccccagag gaagcctgtt ctactcccag ggccaacgct caattgcttg gtaacttggc acccacactg ttccaggctc tggtctcagt ttcactctct gcaaaatgag aggctcagag ttccgctgac atggcctcgg ggccgttaaa acctttcttc atgaagacag cctgcaccct tcctgcttct gctccaggtc catcctcaga accttccaga aagtcctggc acgtcagata acagggccaa cccggcagtg atgccccacc ccccacccct tcccttactc atagagcctg ctccagactc tcagagccca cacccacttg gtgaagtcat ttgccagtaa ttcttcgcac tggacattga gaggtttcag accccagaag tctcaggcgc tgggtctgaa agtgggcaga gcccaggtga catttgtgga gactctcagt ggtgcgtata gccgccggga ccattttcag actcaacctt tctgacctgg aaatgccaat agaagtaatc atcatcgcca ggggctgtgg tgagcaaatg cttggagctc tgtggccagg gcagtttcat ttgaggacca gagatggaca atccctcagc ctactgagat gaagaaactg agtctcagag aggttaagga actcccccga ggttgcacca ctgaggaaga ttgacctgac ttcccaagac catacatctg gtaaaccgga acctgcacct gcgccatctc aagcctactc tggaggcccg aggctaattg gcagagtttg agggctgaga tgacagacaa ccctcagtgc cttcatcggg cgggctgctt acctgcacat ccctggtgac agcatgggaa agaccgcttc taattaagcg tcatcacaca tcaccctttt ccggaggaag agaggcaaag acagctcccc tctatcctgc actgtgaacc ttcctccgag gtcctcccct cacccccgag agtccttgcc ctgtcaccaa gattaattac ccctcaaccc ctttggatgg caaaggcagt cattttatta agtttgatta aagcttcaag agacattgcc ggatgtttca ggactgctga caaagcagcc tgcttgtttc ctgaaaagac caattatatg caagaagcgt cagccccact ccccgagggg tccacttagc ctccgaccac cacagggtga tgtccagcgc accggtgtgg ccatcacctg gcgggagtga ggtcggccgt agcaggtctg gaggcccccc tgcaagtccc tgcctcaccc tgtgactgag cctctcgtct ctgggaattt tgttccaaat tccccgtcta ccaggtgtga tttcctccag ccccaccagc cctgggaggc gcccatccag agagcagaga tggtgaccat gagaaagagg actctcaaag tgctcaccct cctcgtcctc ttcatcttcc tcacctcctt cttcctgaat tactcccaca ccatggtgac caccacctgg tttcccaagc agatggttgt cgagctctca gagaacttta agaagttcat gaaatacact cacaggcctt gcacctgtgc ccgctgcatc gggcagcaga gggtctcggc ctggttcgat gagaggttca accggtccat gcagccgctg ctgaccgccc agaacgccct cttggaggag gacacctaca gctggtggct gaggctccag cgggagaagc aacccaacaa cttgaacgat accatcaggg agctgttcca ggtggtgccc gggaacgtgg accccctgct ggagaagagg tcggtgggct gccggcgctg cgcagtcgtg ggcaactctg gcaacctccg agagtcctgg tacgggcctc agatcgacag ccacgacttc gtgctcagga tgaacaaggc ccccacggcg ggcttcgaga tggatgtcgg gagcaagacc acccaccacc tggtgtaccc cgagagcttc agggagctgg cggagaatgt cagcatggtc ctggtgccct tcaagaccac cgacctggag tgggtggtca gtgccaccac cacaggcacc atctctcaca cctatgttcc tgttcctgca aagatcaaag tgaaaaagga taagatcctc atctaccacc cggccttcat caagtacgtc ttcgacagct ggctgcaggg ccacgggcgg tacccgtcca ccggcatcct ctccgtcatc ttctcgctgc acatctgcga cgaggtggac ttgtacggct tcggggcaga cagtaagggg aactggcatc actactggga gaacaatcca tcggcggggg ctttccgcaa gaccggggtg cacgacggag actttgagtc caacgtgacg gccaccttgg cgtccatcaa taagatccgg atatttaagg ggagatgacg ctgccgagga gcaccggagc ccgcctcttt ggccagcccc agcctctgct ggagccgatc tgtgctgggg gctttgaggg ccagcctcgg gggcgtgttc aggtgcccct cgtgccccct cgcaccccga catttggcag catcgactca gcaaggcccc agagccccgc tgggtctgca gagcgagtgt cagaactggt cttggatggg gacacccccc ctccacctcc ctgcaccgcc actgctgtcc tggagcaggg ggcaggtggg gagacgcggg aggaggtccg gtctccaaac gctcaagtca tttcggcttt ggggggcaga gggggagata tcgaagactc tgtgttctaa agtgaaggac actggccctg ggcagagggg tcccgggctg actctctgac tctgatgctt gctgggtgag gacgacctcg ggacagagcc acatcgggcc acgtggacgc tgggggtgag aaggcacctt cctctgcacg atgcccggcc cctccctcac cgcctctgcg gtcttcccga agctcctccg tggcggccag gagaggcgcc ctgcgccgag ggtcctcaca gatgcttggc caagtgtttc agactccagc aggtgtcttc ttcgcaagct gaggctccct tgagtgatcg atctttgtgg ccataaatga tggctgagag cagatctgac tacttccacg tgcctttgtg tctgggggag agctgtgcgc attggctgaa ataaggcaaa agccttaatt cgggagtggg gagctccccc ctctccccgc ccccagcaat gccaccccct tgctctggag ctgggtaaca tctttactag tttcctgagg cggtgccgga gctggaatga agctaggatg atgctcaacg gcgtccagag gtgcgtcagc cgcggcacgt cattcttagg ttcacagact gatggatttg gggcccgtga ccttccaagg ccacacacag aacctccacc agccagcact ttgccccagg agcccaccct ccaggccaag tccctccggg ccacctgcac agtgtcctgg ggtttgtggg gccatcccag gaacatgacc ctcggagcgg gagaagacat acctcatcct ctcacttctg ggctgctctg attcctcctc atgattattt attgattttt ttttaattca gctgacattg cgtgcacttt gtggctccgt ggctggtcct gatgttttaa ttaagcttgc tctcgcttca cctggcagcc ggggcatggg gggcttaagt caaggtttgc aggagtcctc agacttggga gggggatgca tatctagggc ttgggggctc gtcggtgggc aaatgccagg gtttcaggtt ggtaggttct ccgagtgctc tgtacctcct tcccctcagc tctgcctccc ttctccatca ttgcgggttg ggatcattct caggctaaga atctgcaaaa cccagtgaga cggccttggg gccaggtggg gagtggagtc acacaggcag ggcagcgatg gttggctccg gttgctgaca ctgaatcaga aaatccacgt ttcctattga gagcatttcc taacaggcca ctgctacttc gaggaggtgt gacagtgtcc tggctgtcac gggggcccgt ctcctgtgct ccttgcagca gcactccggc aagttctgct ctcctggctt cagtctctgc ctctgcaaac ggagagggag gcatttgggg agctcagggg gccacaggtg gtttcagggg gttcacaagc gtccccagag agagcacacc acgcccgtgt tttaccccaa gcctgtgtgt atgagcatat attcctgggg agcggtgccg tagcgttcat tcaattgtca gaggttcaga acccagacaa tggtttacaa aaacacgaaa cgacagcaag caaacaaaaa cccgttcgag ctttaaaatc ctccaacact tagactctct tgacccctaa aggctcataa atcactacga ggtcagcaag ctgatcataa atcccaaaga ctatatagca ggcatctgtg ggttggctga tgaatccgct gagagaagtg ggtgcggagc ggcctccgag ctcctccccg agtcctggaa gagccgagtc cagtcagagc tgatgggtcc agagcgctca gcctgcgtcg gggctgtgct gagtcaggac aggtccccag agtaaggggg ggggtctctc tccctcccca ccccactgag ccgtccaggc tgttgagagg acttcccacc tgccttccca tgtaacactt gagaaaagcg aggcccggag aagggaagtg gcttgcaaag tgaacccgtg gtgctggaca acgcaagtca gaccctttga gcaaagatag agcacgattg ctacatgttg aacacacctc gaggtgggct ttcccagccg gcttccatcc agcctcccca aggactgtga ccgggcacag gtgggctcct caggctgcac gtggtggccc ccgcaagctc cggtgtctgc cttttccccc catccctcca gtgagggaga cacccttgct cttccctcag ccccagcaaa cttgtctttg tgttcgttgg cttagcaaag gggtctgacc cgaatgcacc aacgggcttc agccccctgg catctgtacc tggggtaagg gtggctgaga atccaaccag agtatttccc ccagagctcg tggctgtggg caggttaacg agaaccaccc gcccccccca ctcggaggag gctcctgaat gcccacccca gtgttgggct cccagcctag ggccctgctt gctcctcaag cacagagctc ccttggaggc cagtcctgga cccctgggca gggagcagag gcatccctgc ctctctcagt gctgagcccg aagccaggaa gaccagggcc gaggagggag agagagattt taacaccctc cccggccctg gggagccagg agctggagtc acctgccgca aatgcaaggc ctggttccac gtgcccccct ccgcccctgt cctcaccccc ttgttagggt gggtttgtag cgtctggctc ccagagccat caggcaaaaa agaaagttct taaagagatg cttttagggg cctgtgctta gtgggagaag ccagattcaa gaaaatggga cttaaaacgg ggaagccaga cgagaaggtg gggggggggt tgtccgggtg tgattcttac aagtgctgag gccagaagga tggaccctct ccaggtccag agtagagtgg agtcaacggg gaatatttag gactgtgatg tttgcagtaa tggtcctctt caaggcagcc tggacacaaa gcaaaatcgg aaacagaaaa gaactcacca tcccttgcgt gggtaggacc aaaacagctt tctccaggga ggcgcaagcc ctgagtggcc gccgtctggc caaagccggc ctcgtgccat cgggaaccgg ccaccgccca tgcccctccg gagagctcgg ggtcgtcatc gtgtccacca cgggcatctg gtcggaagca aacgttccca caggccactg gctggtcatc gtcccctgtg gtctgggctg accggtttga gaccaagtcc gctgccttgc tccggcctgt cctgaagaca ccagcgcccc ggcctgtggg gtgccccgtg atgcctccat gcagggaaga gcaggggacc agggaggaag agcagagaca ggtgaagcga cagtccccgc gtcccagcct cagcattcgc atcctcttgg cccctacttt tcctctccgc ccagcagaca tctgccctgc ccttgccctt gaccccattg ctgcgcttcc ctcaaggacg ggcctggcct tggtggccac ctgcggacag ccctgcgccc gacgcccgct tcaccccggg gcccgggtct ggaggggccg cccccaggac gaacgcggct gccccacggg gccggcccct caccggcttc gcgtccaagc caaagtttct cgagcacttt tttgttcttt gcaatcatgt tgggttcatt gttggtgttt taaaattttg cttccctctc cctctggcct cgctcctgtg tgtgttttgt agccgagcgc taacctggat gcttttttga atgacctttg caagagcctg ccttcctcgg cctctgctct gttttattta ttgttgaata tttccaatga tccaaatcaa agtgaattaa aacaaagcta ttttatcgtt(配列番号5)(アクセッション番号XM_022426722)を含むイヌST3GalIとの少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%の核酸配列一致;
mvtmrkrtlk vltllvlfif ltsfflnysh tmvtttwfpk qmvvelsenf kkfmkythrp ctcarcigqq rvsawfderf nrsmqpllta qnalleedty swwlrlqrek qpnnlndtir elfqvvpgnv dpllekrsvg crrcavvgns gnlreswygp qidshdfvlr mnkaptagfe mdvgsktthh lvypesfrel aenvsmvlvp fkttdlewvv satttgtish tyvpvpakik vkkdkiliyh pafikyvfds wlqghgryps tgilsvifsl hicdevdlyg fgadskgnwh hywennpsag afrktgvhdg dfesnvtatl asinkirifk gr(配列番号6;アクセッション番号XP_022282430)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子;
cggctcgctc cgggagggca gagccggcaa gggcgggact ggcctgctgc gggcggacgg gggagccgcg gagctaacgg gtccggacgt cgccagcggc ggagctttct gcacgggcgg aggcggcggc aggagcggca agcatggccc gcgcggcgcc cggcgctgac tgagggtcat gctgcggcag cctggcgcct gacgagtgag ggggaacctg ccaggggatt actgctagca cgagctaaca gcaggacagc aggcctcagg ggagtgggga tgggcatagc agcctgcctg caacgctggg ccagtggcac caaggaggcc caggccctgg cagggagctc ggcacacgct cagctgaccc agacagcatt caaagcaggt ccctgctgag cagcagctgt tcccaggccc tggaggaccg caaacgcctc agcaaccaca tttggggctg tgaccatcag gagaagggac caacacctcg aatgggaagc agaagggcag aacctgctgc caggaggatc ttggtctctg cagcaaagtc ttccgacacc cgtggagctt cttgggtttc tcctctcagg actggggcct tgtttcctcc tctggtggag ggggtaggcc aggagggcca gctgaggtgg ggacgactct cggatggaat ccaggccact tgaagcccat gggctctctg ctgtgattgg ggttcgaggg cttccccact gcaggggacg aggggccgcc tccgtgtctg ctcatgaacc acaaggaccc cgaatgctcc agactggacc atttcgagcc accaaagagt ggggccccca gagctggcag ccagcagctc caagggacta gagagctggg atggactgac ctccccctca ccagggcatt aggagagtca gagcctctgt ggcccagcta gtgacagaga gacccgatga ggccataagc tggcacccga gtgactcagg gacaggagag ccactcctgc ctactgtgct ttctctttac attgagggag ggtgtggtaa gggacccctg cctctgttcc ctcctcagca cgtgccccta tgccctttgc acgtggtgcc aggagacgca ggctacactg tggctggccc atcagtgggc tgggaaggga gtggccacgg tgacacccac ccgcccacca ggctggtggt ctagcccccc ggggcgccaa accatgaagt gctccctgcg ggtgtggttc ctctctgtgg ccttcctgct ggtgttcatc atgtcactgc tctttaccta ctcccaccac agcatggcca ccttgcccta cctggactca ggggccctgg gcggtaccca ccgggtgaag ctggtgcctg gctatgctgg tctgcagcgc ctcagcaagg aggggctcac cggtaagagc tgtgcctgcc gccgctgcat gggtgacact ggcgcctctg actggtttga cagccacttc aacagcaaca tttcccctgt gtggacccga gagaatatgg atctgcctcc agatgtccag aggtggtgga tgatgctgca gccccagttc aagtcacaca acaccaacga ggtactggag aagctgttcc agatagtacc aggcgagaac ccctaccgtt tccgggaccc ccaccagtgc cggcgctgtg cggtagtggg gaactcaggc aacctgcggg gctctggcta cggcccagat gtggatgggc ataacttcat catgaggatg aatcaggcgc caaccgtggg ctttgagcag gatgttggca gccgaactac ccaccatttc atgtaccccg agagtgccaa gaaccttcct gccaacgtca gctttgtgtt ggtgcccttc aaagctctgg acctactatg gattgccagc gctttgtcca cagggcaaat cagattcacc tatgcgccag tgaagtcctt ccttcgagtg gacaaagaaa aggttcagat ctacaacccg gcattcttca agtacatcca cgaccggtgg acagagcatc acgggcggta cccttccaca gggatgctgg tgctcttctt tgccctgcat gtttgtgatg aggtgaacgt gtacgggttc ggggccgaca gccggggcaa ctggcaccac tactgggaga ataaccggta tgcgggcgag ttccggaaga cgggagtgca cgacgccgac ttcgaggccc acatcatcga catgctggcc aaggccagca agatcgaggt ctaccgaggc aactgagccc ggcctcgccg cgacccttcc ggcccagccg cgaggctgcg acgctcgctc cgcagccggg actcccggcc agcccgaggg cggcggcctt ggcgagggcg cggcgcccgg ttgggcgtct ccagccctgg gagcgacgcc aagtcgcggt ctggaccaat catgctgcaa gtccagcgag cgccggctgt cccccgccaa tcaggagact ttgggggctg gcccaggcct ggcacccaat cagcgctgca gtgggagcgg aggctctttc tcccagccaa tcatgcgact caaggagaac ttccggcgct gggcccggtc tcctccaatc aatggccttc ggaggcgggc cggccgccgc tgaatcccca ctcccctatg ctttgggtag gattttattt tatgcttttt aaggagtagt ggttggttcc ggcctcagtg gagtactttc ctcaggctct gcgggaggag tgttggtggc ctgtcggcgg tactcggcca ggggcaccga ggaggaagcg ggggggaagg tgcggggcag cagcggctgg gcctcccttg gccgggggcc cctcgcgacc tcggggcggg cgggggggcg ggggcgttgg cctcccgctt ctggaggtcc ggggggaatc aggtggtttc cggggagcgc gctttcatcc ccgggaagag ctagatccct ctcaaacctt ttcaggcctc agagcactct agaccgcgta tttcctttat ctgtcgggcc cagatgggtg agtgtaaacc caccaaagaa aggcagtgga gcgtgggtcc cctcgtcctc ccttgtcccc atccccacct ttggccaccc tatgggatgg ccttcctgac cagggcattg agcatcccac ctggaaacta gaactgtatt cacccgttgc tagggctcgg agttcgccga tggcctaact cgagcgcagg ggtaaggaac agggcagggg acccggaagc cccgtcactt cagatgtaag gtgcttctca ctctcgtgta ctctcgcggc cccttactgt tcgcccacaa cttttttagt gtcccttctt aagccctggg cctcctcacc agcctgctcg tcctgggatt gggggtgggg ggtggggcac tgctggcttc tccaaccccc tacccctcct cgctcgtctt tagccggctc tagggagagg aaggcaggct ggagatgggg agcccagctg cctggtgcat gcaccgtttt cctccgccca tcaccccaaa gaggagtagg aaacctcttg cttgggggtg gaatttgctt tggtctccta atttagttaa cttgaggtta ccagggatgg ctgaccaaca aagattcttt taaaattcca ggctggccat gcaaattgct gggatcctag ctggggagga gtcgactgac ttgcccgcct tgcatgtctc ctctcctgcc cctgcgtccc ctccctctgc cacgctcact tcctgcctca tctctccaac ccattttcca ttttcagctc tagaagggca gggacgctta caaacaggag ttacatctgg aagttacttc caagactgaa cccagcttaa gtccctagag gaagctgctg atgatattct cacccttcaa ggttggggaa gtttcggagg gggaaagtgc ttctgtgaag cttccaaacc actaatagga tcccccttcc caacaatgag gaacacaaac accacccttt atcttagttg ataccaccaa gcagcctcct ggccattggg gtaattcctg cagctggctg gggtaaccag caggggagta tattagagga ggattggggc agggcagtgg gcacccctaa agttaatata ttgagaactt agcttaagcc taagtcttag ttccttccca attccaaaag taggaggagc aacgagtggg ggtggatttg ggggggccta tcctggaatg cctctctcag ggcttccccc accattttag agagtcaagg caccagccat tcatgccagt ctcctctcag tgcttcctga agaggctgtt tggagtgttc ggaaaatgaa aaaaacaatg caattatgcc aaacagtatt gagcagaata atttatttct tttttgttcc tttttcttct ttttgttttg tttaaaacat taataaatcc cctttctgga agaggtaggt cccagcatcc agcccagatc tccttttctg caatagttat ttaaacaaat gtttgtttgt ttttttattt tcttcccttt ctctctcttt ctgaattaaa aaaaaagaaa actccta(配列番号7)(アクセッション番号XM_014114023)を含むイヌST3GalII遺伝子と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致する核酸配列を持つST3遺伝子;
mkcslrvwfl svafllvfim sllftyshhs matlpyldsg alggthrvkl vpgyaglqrl skegltgksc acrrcmgdtg asdwfdshfn snispvwtre nmdlppdvqr wwmmlqpqfk shntnevlek lfqivpgenp yrfrdphqcr rcavvgnsgn lrgsgygpdv dghnfimrmn qaptvgfeqd vgsrtthhfm ypesaknlpa nvsfvlvpfk aldllwiasa lstgqirfty apvksflrvd kekvqiynpa ffkyihdrwt ehhgrypstg mlvlffalhv cdevnvygfg adsrgnwhhy wennryagef rktgvhdadf eahiidmlak askievyrgn(配列番号8)(アクセッション番号XP_013969498)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子;
ttggtggtcg cgctccgccc gccgctgcgt ccccaccatg gcggcgcccg tgcagcccac cgcgtcgtgg gcgcccgccg ggctcccccg cggctgtggc ggccgcccgc gcctcggcct ccgcctcccc gcccgcgccg gcccgggcgc cgcctccccg ctgcctccgt ctccgctgcg gtcatgtagg aaatcgtaaa tcatgtgaag atgggactct tggtatttgt acgcaatctg ctgctagccc tctgcctttt tctggtactg ggatttttgt attattctgc gtggaagctg catttactcc agtgggagga ctccaattca gtggttcttt cctttgactc cgctggacaa acactaggct cagagtatga tcggttgggt ttcctcctga agctggactc taaactgcct gctgagttag ccaccaagta tgcaaacttt tcagagggag cttgcaagcc tggctatgct tcggccttga tgactgccat ctttccccgg ttctccaagc cagcacccat gttcctggat gactctttcc gcaagtgggc taggattcgg gagtttgtgc cgccttttgg gatcaaaggt caagacaatc tgatcaaagc catcttgtca gtcaccaaag agtaccgcct gacccctgcc ttggacagcc tcagctgccg ccgctgcatc atcgtgggca acggaggtgt cctagccaac aagtctctgg ggtcacgaat tgatgactat gacattgtgg tcagactgaa ctccgcacca gtgaaaggct ttgagaagga cgtgggcagc aaaactacac tgcgcatcac ctaccctgag ggcgccatgc agcggcctga gcaatatgaa cgcgattctc tatttgtcct cgctggcttc aagtggcagg acttcaagtg gttgaagtac atcgtctaca aggagagagt gctctgggcc cgcagggata cctgccaatc tgtctgggcc catccccctc tcccctccac cagctgtcac cagccacccc aggggagggg tcctgcagag ttcaggccat tcttcttcca atacccgagc ctcctactgg aggagaatga tgacagacag cctctggcga caagtgcatc agatggcttc tggaaatccg tggccacacg agtgcccaag gagccccctg agattcgcat cctcaacccg tacttcatcc aggaggccgc cttcaccctc atcggactgc ccttcaacaa cggcctcatg ggccgcggga acatcccgac ccttggcagt gtggcagtga ccatggcgct acacggctgt gatgaggtgg cagtcgcagg ctttggctac gacatgagca cacccaacgc gcccctgcac tactatgaga ccgtgcgcat ggcagccatc aaagaggtca ccagcgactc agctcaaggc tgccaaatcc agtggacaca tggaagcctc atctttcctg acctcccaga aatgcttttt ctgttgacca ctccttcctc tttgaaactt ttcctgctca gactgtcctg gacacacaat atccagcgag agaaagagtt tctgcgcaag ctggtgaagg cgcgcgtcat caccgaccta accagcggca tctgaggtgg gcccagcaca tggccacgga ggtcctggca ccgccaagag gaagccgcag ccactgccac ctgtccactt cattggcctc ggtctggctc tgcctgaaag gcgcaggagt cttcagaccc agagaaggac agtgccaagg gg(配列番号9)(アクセッション番号XM_025420404)を含むイヌST3GalIII遺伝子と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致する核酸配列を持つST3遺伝子;
mgllvfvrnl llalclflvl gflyysawkl hllqwedsns vvlsfdsagq tlgseydrlg fllkldsklp aelatkyanf segackpgya salmtaifpr fskpapmfld dsfrkwarir efvppfgikg qdnlikails vtkeyrltpa ldslscrrci ivgnggvlan kslgsriddy divvrlnsap vkgfekdvgs kttlritype gamqrpeqye rdslfvlagf kwqdfkwlky ivykervlwa rrdtcqsvwa hpplpstsch qppqgrgpae frpfffqyps llleenddrq platsasdgf wksvatrvpk eppeirilnp yfiqeaaftl iglpfnnglm grgniptlgs vavtmalhgc devavagfgy dmstpnaplh yyetvrmaai kevtsdsaqg cqiqwthgsl ifpdlpemlf llttpsslkl fllrlswthn iqrekeflrk lvkarvitdl tsgi(配列番号10)(アクセッション番号XP_025276189)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子;
gccctacagg cccgagctgc cggggtcggg cctccccggg ttcccgctcc cgggtcctcc tggacacacc ggcctggcct ggctcccggg gaactctcgt ctgctagcgg ggagcctccc tccgcctcgc ccacgggcac ccctcccacc cagtatcctt ggcctcttgc aggtggcccg aggcagccgg gatgacagct ctccccagga accctgctac cctctgagaa acatgatcag caagtcccgc tggaagctcc tggccatgtt ggctctggtc ctggtcgtca tggtgtggta ttccatctcc cgagaagaca ggtacattga gcttttttat tttcccatcc cagagaagaa ggaaccgtgc ttccagggtg aggcagagag aaaggcctct aagctctttg gcaactactc ccgagatcag cccatcttcc tgcagatgaa ggattatttc tgggtcaaga caccgtctgc ctacgagctg ccctatggga ccaaggggag cgaagacctg ctcctccggg ttctagccat caccagctac tccattccag agagcatcca gagtctcaag tgtcgccgct gcgtggtggt gggcaatggg catcggctgc gcaacagctc gctgggagat gccatcaaca agtacgacgt ggtcatcaga ctgaacaacg cccccgtggc tggctacgag ggtgacgtgg gctcgaagac caccatgcgt ctcttctacc cggagtcagc ccacttcaac cccaaagtgg agaacaaccc agacacactt ctcgtcctgg tggccttcaa ggcaatggac ttccactgga ttgagaccat cctgagtgat aagaagaggg tacgaaaggg cttctggaag cagcctcccc tcatctggga cgtcaacccc aggcaggttc ggattctcaa ccctttcttt atggagattg cagctgacaa actgctgaac ctgccaatga aacagccacg caagatttcc cagaagccca ccacgggcct gctggccatc acgctggctc tccacctctg cgacctggtg cacatcgccg gcttcggcta cccggacgcc cacaacagga agcagaccat tcactactat gaacagatca cgctcaagtc catggcgggg tcaggccaca acgtctccca ggaggccctg gccatcaagc ggatgctgga gatcggagca gtcaagaacc tcacgttctt ctgacgggga caggagctct agccgtcagt ctgcccgccc tgccgcctga gcgaccaacc acggctgtgg gggcgccggc gtgacctgct tggattcccc ctccccgtgt ggagaggggg cctggtacag gcggggcctg agatggggcc gcgcccctgg ctgctcttgg ggcggccgga tccagtcagg gtggaggccc cgggtggcgg gaggccttcc gaggcgcggg gtgtgtggct gaggcacccc ttctcaccag ccccgggagc ttatttaatg ggctatttaa ttaaaagggt aggaatgtgc ctcgggctgg tcccatggca tccggaaacg ggggcatagc acagtggtct gcccactgtg gataaaaaca cacaagtgct tggcccacta gagcctagag ccagagcagg cctcccagga gggcaggggc gtctggagcg ggtgggtgcc ctccagagag gggctgctac ctcccagcgg gcatgggaag agcattggga tgaggtccca cggagaatgg gacctcatgt agaaaagagg tttgaaacct aacattaaac tattttttcc taaaacggaa(配列番号11)(アクセッション番号XM_014113293)を含むイヌST3GalIV遺伝子と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致する核酸配列を持つST3遺伝子;
misksrwkll amlalvlvvm vwysisredr yielfyfpip ekkepcfqge aerkasklfg nysrdqpifl qmkdyfwvkt psayelpygt kgsedlllrv laitsysipe siqslkcrrc vvvgnghrlr nsslgdaink ydvvirlnna pvagyegdvg skttmrlfyp esahfnpkve nnpdtllvlv afkamdfhwi etilsdkkrv rkgfwkqppl iwdvnprqvr ilnpffmeia adkllnlpmk qprkisqkpt tgllaitlal hlcdlvhiag fgypdahnrk qtihyyeqit lksmagsghn vsqealaikr mleigavknl tff(配列番号12)(アクセッション番号XP_013968768)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子;
cgctctggaa ccacttacag ccacctggtg catcctcctt tggggtgcgt ttggagggcc tggttcctgc tcagccacat cttctgccac tttcaccagc aatgcccagt gagtataact atgtaaaact gagaagcgat cgctcaagac cctctctgca atggtacacc cgagctcaaa acaagatgag aagacccaac ttgttgttaa aagacatcct taagtgtaca ttgcttgtgt ttggagtgtg gatcctttat attctcaagt taaattatac tactgaagaa tgtgacatga aaaaaatgca ttatgtggac ccagaccgtg taaagagagc tcagaaatat gctcagcaag tcttgcaaaa ggagtgccga cccaagtttg cgaagaagtc gatggcgcag ttgttcgagc acaggtacag cacggacttg ccacctttcg tgaaggagac ccccaaaatg aatgaagccg agtacaagta tgatcctcct tttggattcc gaaagttctc cagtgaagtc cagaccctgt tggaaatact gcccgagcat gacatgcccg aacacttgag agcaaagagc tgtaggcgtt gtgtggtcat cggaagcggt ggcatactcc acggactagc actgggccag gccctcaacc agttcgatgt ggtgataagg ttaaacagtg caccagttga gggatattct gagcatgttg gtaataaaac tactataagg atgacttatc cagagggcgc gccactgtct gaccttgaat attattccaa tgacttgttt gttgctgttt tattcaagag tgttgacttc aactggcttc aagcaatggt aaaaaatgaa accctgccat tttgggtgcg gctcttcttt tggaagcagg tggcggaaaa aatcccacta cagccaaaac atttcaggat tttgaatcca gttattatca aagagactgc ctttgacatc cttcaatact cagagcccca gtcaaggttc tggggccgag ataagaacgt gcccaccatt ggtgtcattg ccgttgtctt agccacacat ctgtgtgatg aagtcagctt ggcaggcttt ggatatgacc tcaatcaacc caaaacacct ttgcactact ttgacaatct ctgcatggct gccatgaact ttcaaaccat gcataatgtg acaacggaga ccaggttcct cctcaagctg gtcaaagagg gcgtggtgaa ggatctcagc ggaggcatcc attgtgaatt ttgaacacag ggaaacctca tgtgacaatg caactctgac tctgaaggct gtttttcgta gccttctcga tgcagcgcat cctgcaaaat acttagaggt gcagctgggg ttttt(配列番号13)(アクセッション番号XM_022404744)を含むイヌST3GalVと少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致する核酸配列を持つST3遺伝子;
mpseynyvkl rsdrsrpslq wytraqnkmr rpnlllkdil kctllvfgvw ilyilklnyt teecdmkkmh yvdpdrvkra qkyaqqvlqk ecrpkfakks maqlfehrys tdlppfvket pkmneaeyky dppfgfrkfs sevqtlleil pehdmpehlr akscrrcvvi gsggilhgla lgqalnqfdv virlnsapve gysehvgnkt tirmtypega plsdleyysn dlfvavlfks vdfnwlqamv knetlpfwvr lffwkqvaek iplqpkhfri lnpviiketa fdilqysepq srfwgrdknv ptigviavvl athlcdevsl agfgydlnqp ktplhyfdnl cmaamnfqtm hnvttetrfl lklvkegvvk dlsggihcef(配列番号14)(アクセッション番号XP_022260452)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子;
ST3遺伝子ggtcgattgc cccttggctg ctgtggaggc tgtgatgacc tccagggccg cggccctccg ggcgatgctt ctccaggggc tgaggccaac gcagaactcc cgtggcaccc actcggactc gcggcgtgtt cacatgtggg gttttattaa atcctcccac caaccgtgtg agacaggaac agttagcccc ggtgtgtccg ccaagattgc cccgcacaag tggctccgga tggatcacac gaagcacttg caagtgaaga agcagcacag ccctttatct tgggctattt cctgtggaga gactccaaca atttagcagc caggctcctg ggcctctggg accctcacca catcacatcc ttcaccttca ggagcagagc gcctttggga aacagacttc taaaagtgca ggtgggccag ccatgagagg gtacctagtg gccatattcc tgagtgctgt ctttctctat tatgtgctgc attgtatatt gtggggaaca aacatctatt gggtgccacc tgtggaaatg aagcggagaa ataagatcca gccttgttta gcgaagccag cttttgcctc tctcctgagg tttcatcagt ttcacccttt tctgtgtgca gctgatttta aaaagattgc ttccttgtat ggtagcgata agtttgatct gccctatggg ataagaacat cagcggaata ttttcgactc gctctttcaa aactgcagag ttgtgatctc tttgatgagt ttgacaatgt gccgtgtaaa aagtgcgtgg tggttggtaa tggaggagtt ctgaagaata agacattagg agaaaaaatt gactcctatg atgtcataat aagaatgaat aatggtcctg ttttaggaca tgaagaggaa gttgggagaa ggacaacctt ccgacttttt tatccagaat ctgttttttc agatcccaat cacaatgatc ctaatactac agcgattctc actgctttta agccgcttga cttaaagtgg ctgtgggaag tgttgacggg tggcaaaata aacactaatg gtttttggaa gaaaccagct ttaaacttga tctacaaacc ttatcaaatc agaatattag atcctttcat tatcagaatg gcagcttatg aactgcttca cttcccaaaa gtgtttccca aaaaccagaa acccaaacac ccaacaacag gaattattgc catcacgctg gcctttcaca tatgtcacga agttcacctt gctggtttta aatacaattt ttctgacctc aagagccctt tacactatta tgggaacgcg accatgtctt tgatgaataa gaatgcgtat cacaatgtga cagcggaaca gctctttttg aaggacattc tagaaaaaaa ctttgtaatc aacttgactg aagattgacc ctacagactc tgcagatgat gctaagagta ttagttttat ttttatactg caatttttag tttattttta aatatgttgg atgcacttgt caaaaaattg tgtatagtca gtctgttgct gcctggtgat tcataaccac cagcttaatt tctgtgaata tatttaattt ataaaaacca agaagatatg cttagatatc cgggaagttt tgattgcgtt ggttttaaaa caaccttagt tctctgaagt gtttttaaac atctttttta atagttactt catctttgac ttctgagggc atgtgacgtc caagtaaggg gctttagctt gaccaccaca aactctgaac agagttggtg gcggattcgg ctactgtaaa ttggtgggga atagccatgt gattgtgcaa actggaaccg gtttaggcaa gtatcgagtt cctttttact gaacccgagg aaacggattt gaatcttaaa gcaggcccaa ccatagcagt aggtacggtt atgaaatcta agatcataat ggtttcatta agcttttttt cctgtaagta aaccagatta taaaatgaaa ggtgtttgtt tttaaggtgg aggaaacagg ctacatgtga aattctggat gagtaaacaa cctaggaatg caattactaa agtctggtgg ctgcattatt ttaaagttca tacaaagaag cagagctagg ccacctcaag gagacagttc ttaaacgtca tcttttgcct gccttaatat gttaaaattt ggaagtttac tatttgaaat aggaaagatg aatacggcac agtaggtaaa tccttcagac tcctcaggct gtttttggat ttaaatggtc ctttcgtgaa aaatctcact tgtccacggt gaaatcccat cttcaaaggg aaggcttacc cggctaccta gggtgcatca gagaagagtc ctgctggatg cagacaagtc aaaaccagcc tgtccaacaa acgtgcgccc gtctctcttc tcaaagaggg atggaatgaa cagctctcag aagaggtaag agttgaagga cttgttatcc tctgagcgat aatcgtcatg gagagacact gctggtgttc ctgaaaacca gcctgcctct gagtctcaga gacaaaatat gagagcagcc actgggataa atcgtgaagc acggcataag gggggagaag cctcgtagtt gattgaaccc atgtctacgt ggcttcagct gattcccctg taacggaggt ggaaagttcc cgcacgtaca cagctgcacg ctgcagcctg gcggctggga ttccatgggt ggactcattc agggtacaaa gacagtcctg gctgcaaagt gaaaaacccc aggtggcatt ttcaagtgtt tatggactga aataatggct gtacggtatc tggcggatgc tcaacttgag gaatcggcat ttttgtacag tgggagctga ggctataaac ctcagcgtgg cttcacataa gccagaagaa actctcagcc cgatacatat gtacaattta ttaaaaacac atgaacacgt taaaatctca ctatttatac aatctacatt ctagcaacat atacaaatac cgagtgacta cagtacatgc cgaggtaaga aaagtacatt cggggagact atcactgaca ctcaagccat ttttatttcc aatatgtttt gctttcacct ttcccagtgc caaaaaaaaa aaaaaaaaa(配列番号15)(アクセッション番号XM_005639375)を含むイヌST3GalVIと少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致する核酸配列を持つST3遺伝子;
mrgylvaifl savflyyvlh cilwgtniyw vppvemkrrn kiqpclakpa fasllrfhqf hpflcaadfk kiaslygsdk fdlpygirts aeyfrlalsk lqscdlfdef dnvpckkcvv vgnggvlknk tlgekidsyd viirmnngpv lgheeevgrr ttfrlfypes vfsdpnhndp nttailtafk pldlkwlwev ltggkintng fwkkpalnli ykpyqirild pfiirmaaye llhfpkvfpk nqkpkhpttg iiaitlafhi chevhlagfk ynfsdlkspl hyygnatmsl mnknayhnvt aeqlflkdil eknfvinlte d(配列番号16)(アクセッション番号XP_005639432)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子;
aaagacttca ctgggtatca gtctcctttg ggagaccaca ggacacgtgt cacctctccc atcctctcag cctccagccc agaccttggc agagttcctt ttaggagtta gcaagtggct gaggaggcaa gaggtgccag agccaatcta ctatctgctg ggggatgatt gccagggcca gagatgaggg ctcaatactt gaagtggggt ctggtagctg cctgtatagt tacgttatgg ctgatgatga tgaacttcct ggaccaggag ttcaaacaga atgacttccc taaaaagaca agaatacaat tatgccactg ccccaggaac tctttcagaa agtgtaggtg ttcgtttgag atccgcaagt gctctgcctg cctccgcgta cgtggaacgt ctgtctggtt tgatgaacgc ttcgaaacgg ctattgagcc tgtgcagaga ccagaagatc ccatatcctc tgatgctctg atattgtggt tgggtgtcca atcaaagagg gagtttgaga ctcagaagcc aatagaagag cctcctgggc aaccactggg ctacgtggag tccagttgtc ggacctgtgc agtggttgga aactcaaggt gcctacgggg ctctggccat ggattcagga ttaaccaaaa tgacatggtc ctcaggatga accaggcccc cgtccaagga tttgagatgg atgtggggaa cacaaccacc atgcgcataa tgtaccccga tatggctagc acgcagaatc ctggcaccaa attgctgctg cttcctctga attcatctgg tctaaagtgg tttatggaag tactacagga acagagcttc agaaagccca taaaccctgg atttcagata gtccagtttc ctggtggaag taacacgagc aaagacgagg tcttggtgat cagcctcacc tttcttcagt acatccagga tcattggctg cgaaaacgtc atcgttttcc atccttgggg tttgtgggtc tgttatatgc cctgcacact tgtgaccagg tatccttatt tggttttggg acagatcagc tcatgaggtg gtcccattac tgggatgata aatatcggtt cgagagtaac atgcacagtt tcaaagaaga gcagaagctc atcctccagc tgcaatgtga ggggaagatt gttatctaca gctgacatgt ttctgtcctg ttcagcccac tggaggcccc aggaggctga caggtagtca aggggaccac agagtgtcag agagggactg gggcttcaag tggaccctgg atatagatca gtctgctgct aaataaaact acagcttatt tctccca(配列番号17)(アクセッション番号XM_025469036)を含むイヌST3GalII様と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致する核酸配列を持つST3遺伝子;または
mraqylkwgl vaacivtlwl mmmnfldqef kqndfpkktr iqlchcprns frkcrcsfei rkcsaclrvr gtsvwfderf etaiepvqrp edpissdali lwlgvqskre fetqkpieep pgqplgyves scrtcavvgn srclrgsghg frinqndmvl rmnqapvqgf emdvgntttm rimypdmast qnpgtkllll plnssglkwf mevlqeqsfr kpinpgfqiv qfpggsntsk devlvisltf lqyiqdhwlr krhrfpslgf vgllyalhtc dqvslfgfgt dqlmrwshyw ddkyrfesnm hsfkeeqkli lqlqcegkiv iys(配列番号18)(アクセッション番号XP_025324821)と少なくとも80%、85%、87%、90%、92%、95%、96%、97%、98%、または99%一致するアミノ酸配列を持つタンパク質をコードするST3遺伝子を持つ。
1この配列は PX459ベクターの一部の配列と一致していた。
Bates et al., J. Stat. Softw., 61:1 (2015).
Chambers et al., Cell Rep., 12:1 (2015).
Chambers et al., J. Viral, 88:10986 (2014).
Chu and Whittaker, Proc. Natl. Acad. Sci. U.S.A., 101:18153 (2004).
Cong et al., Science, 339:819 (2013).
Connor et al., Virology, 205:17 (1994).
Gamblin and Skehel, J. Biol. Chem., 285:28403 (2010).
Han et al., Cell Rep., 23:596 (2018).
Hatakeyama et al., J. Clin. Microbiol., 43:4139 (2005).
Hegde, Hum. Vaccine Immunother., 11:1223 (2015).
Hidari et al., Biochem. Biophys. Res. Commun., 436:394 (2013).
Jinek et al., Science, 337:816 (2012).
Lee et al., PLoS One 8 (2013).
Lenth, J. Stat. Softw., 69 (2016)
Li et al., J. Clin. Microbial., 47:466 (2009).
Lin et al., Influenza Other Respir Viruses, 11:263 (2017).
Lin et al., J. Viral., 84:6769 (2010).
Lin et al., PLoS One, 12, 72299 (2017).
Matrosovich et al., Journal of Virology, 77:8418 (2003).
Mohr et al., Viral J., 12:67 (2015).
Oh et al., J. Clin. Microbial., 46:2189 (2008).
Rogers and Paulson, Virology, 127:361 (1983).
Shalem et al., Science, 343:84 (2014).
Shibuya et al., J Biochem., 106:1098 (1989).
Shinya et al., Nature, 440:435 (2006).
Skowronski et al., Euro. Surveill., 21:30112 (2016).
Stevens et al., J. Mal. Biol., 355:1143 (2006).
Takashima and Tsuji, Trends in Glycoscience and Glycotechnology, 23:178 (2011).
Tamura et al., Antimicrob. Agents Chemother., 57:6141 (2013).
van Riel et al., Science, 312:399 (2006).
Zhu et al., J. Viral, 86:13371 (2012).
Claims (33)
- 哺乳類または鳥類の対応する非組み換え細胞と比べて減少した量の細胞表面β-ガラクトシドα2,3シアリル残基と増加した量のヒトβ-ガラクトシドα2,6シアリル残基を含む哺乳類または鳥類の単離された組み換え細胞。
- 非ヒト細胞である、請求項1の単離された組み換え細胞。
- イヌ細胞または霊長類細胞である、請求項1または2の単離された組み換え細胞。
- ヒトβ-ガラクトシドα2,6シアリルトランスフェラーゼI(ST6Gal-I)またはST6Gal-IIをコードする発現カセットを含む、請求項1~3のいずれか1項の単離された組み換え細胞。
- 前記ST6Gal-IまたはST6Gal-IIが、配列番号1~4または101のいずれか1つとアミノ酸配列が少なくとも80%一致するタンパク質を含む、請求項4の単離された組み換え細胞。
- 1つ以上のβ-ガラクトシドα2,3シアリルトランスフェラーゼ遺伝子が変異して細胞表面β-ガラクトシドα2,3シアリル残基の量が減少している、請求項1~5のいずれか1項の単離された組み換え細胞。
- ST3Gal-I遺伝子、ST3Gal-II遺伝子、ST3Gal-III遺伝子、ST3Gal-IV遺伝子、ST3Gal-V遺伝子、ST3Gal-VI遺伝子、またはST3Gal-II様遺伝子の2つ以上が変異している、請求項6の単離された組み換え細胞。
- 前記ST3遺伝子が、配列番号5、7、9、11、13、15、または17のいずれか1つと少なくとも80%一致する核酸配列を持つ、請求項7の単離された組み換え細胞。
- 細胞表面β-ガラクトシドα2,3シアリル残基の前記減少が、1つ以上のST3シアリルトランスフェラーゼの発現が減少した結果である、請求項1~8のいずれか1項の単離された組み換え細胞。
- 前記1つ以上のST3シアリルトランスフェラーゼが、配列番号6、8、10、12、14、16、または18のいずれか1つと少なくとも80%一致するアミノ酸配列を持つ、請求項9の単離された組み換え細胞。
- インフルエンザH3ウイルスが、前記組み換え細胞の中で前記非組み換え細胞と比べてより効率的に複製される、請求項1~10のいずれか1項の単離された組み換え細胞。
- 哺乳類または鳥類の対応する非組み換え細胞と比べて減少した量の細胞表面β-ガラクトシドα2,3シアリル残基を含む、哺乳類または鳥類の単離された組み換え細胞。
- ST3Gal-I遺伝子、ST3Gal-II遺伝子、ST3Gal-III遺伝子、ST3Gal-IV遺伝子、ST3Gal-V遺伝子、ST3Gal-VI遺伝子、またはST3Gal-II様遺伝子の1つ以上が変異している、請求項12の組み換え細胞。
- ST3Gal-I遺伝子、ST3Gal-II遺伝子、ST3Gal-III遺伝子、ST3Gal-IV遺伝子、ST3Gal-V遺伝子、ST3Gal-VI遺伝子、またはST3Gal-II様遺伝子の組み合わせが変異している、請求項12の組み換え細胞。
- ST3Gal-I遺伝子、ST3Gal-II遺伝子、ST3Gal-III遺伝子、ST3Gal-IV遺伝子、ST3Gal-V遺伝子、ST3Gal-VI遺伝子、およびST3Gal-II様遺伝子が変異している、請求項14の組み換え細胞。
- 哺乳類細胞上または鳥類細胞上の細胞表面β-ガラクトシドα2,3シアリル残基とヒトβ-ガラクトシドα2,6シアリル残基の量を変化させる方法であって、
親哺乳類細胞または親鳥類細胞の中で1つ以上のβ-ガラクトシドα2,3シアリルトランスフェラーゼ(ST3Gal)遺伝子を変異させるとともにヒトβ-ガラクトシドα2,6シアリルトランスフェラーゼI(ST6Gal)遺伝子を過剰発現させて、対応する親細胞と比べて減少した量の細胞表面β-ガラクトシドα2,3シアリル残基と増加した量のヒトβ-ガラクトシドα2,6シアリル残基を表面に持つ改変された哺乳類細胞または鳥類細胞にすることを含む方法。 - ゲノム編集システムを利用して1つ以上のST3Gal遺伝子を変異させる、請求項16の方法。
- 前記ゲノム編集システムが、CRISPR/Cas9、ジンクフィンガーヌクレアーゼ(ZFN)、または転写アクチベータ様エフェクタヌクレアーゼ(TALEN)を含む、請求項17の方法。
- 前記変異が、1つ以上のヌクレオチドの挿入、または1つ以上のヌクレオチドの欠失、またはその両方を1つ以上のST3遺伝子の中に含む、請求項16~18のいずれか1項の方法。
- 前記改変された細胞が、ST6Galオープンリーディングフレームを含む発現カセットを含む、請求項16~19のいずれか1項の方法。
- 前記改変された細胞が腎細胞である、請求項16~20のいずれか1項の方法。
- 前記改変された細胞がイヌ細胞である、請求項16~21のいずれか1項の方法。
- 前記改変された細胞がMadin-Darbyイヌ腎(MDCK)細胞である、請求項16~22のいずれか1項の方法。
- インフルエンザウイルスを増殖させる方法であって、
請求項1~11のいずれか1項の組み換え細胞にインフルエンザウイルスを感染させ;
子孫ウイルスを回収することを含む方法。 - 前記インフルエンザウイルスがヒトインフルエンザウイルスである、請求項24の方法。
- 前記インフルエンザウイルスがA型インフルエンザウイルスである、請求項24または25の方法。
- 前記インフルエンザウイルスがB型インフルエンザウイルスである、請求項24または25の方法。
- 前記インフルエンザウイルスがH3ウイルスである、請求項24、25、または26の方法。
- 前記ウイルスが、A/H1N1、A/H3N2、B/山形系統B型インフルエンザウイルス、またはB/ヴィクトリア系統B型インフルエンザウイルスである、請求項24、25、または26の方法。
- インフルエンザウイルスを単離する方法であって、
インフルエンザウイルスに感染していることが疑われる鳥類または哺乳類からのサンプルを用意し;
請求項1~11のいずれか1項の組み換え細胞に前記サンプルを接触させることを含む方法。 - 前記サンプルにインフルエンザウイルスが感染しているかどうかを判断することをさらに含む、請求項30の方法。
- 前記ウイルスのHA亜型および/またはNA亜型を同定することをさらに含む、請求項30または31の方法。
- インフルエンザウイルス感染を診断する方法であって、
請求項1~11のいずれか1項の組み換え細胞に、インフルエンザウイルスに感染していることが疑われる鳥類または哺乳類からのサンプルを感染させ;
その細胞がウイルスに感染しているかどうかを判断することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962803266P | 2019-02-08 | 2019-02-08 | |
US62/803,266 | 2019-02-08 | ||
PCT/US2020/017342 WO2020163804A1 (en) | 2019-02-08 | 2020-02-07 | Humanized cell line |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022522112A true JP2022522112A (ja) | 2022-04-14 |
Family
ID=69960694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021546853A Pending JP2022522112A (ja) | 2019-02-08 | 2020-02-07 | ヒト化細胞系 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11851648B2 (ja) |
EP (1) | EP3921413A1 (ja) |
JP (1) | JP2022522112A (ja) |
CN (1) | CN113874496A (ja) |
WO (1) | WO2020163804A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11802273B2 (en) | 2014-06-20 | 2023-10-31 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
US12076387B2 (en) | 2010-03-23 | 2024-09-03 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US12122807B2 (en) | 2022-07-18 | 2024-10-22 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115772502B (zh) * | 2022-06-28 | 2024-03-15 | 中国生物技术股份有限公司 | 唾液酸转移酶基因缺失的mdck细胞株及构建方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100021499A1 (en) * | 2008-06-11 | 2010-01-28 | Flugen, Inc. | Cell-based systems for producing influenza vaccines |
US20130243744A1 (en) * | 2011-01-06 | 2013-09-19 | Michael J. Betenbaugh | Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells |
JP2017506903A (ja) * | 2014-03-04 | 2017-03-16 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC | ウイルス耐性細胞及びその使用 |
Family Cites Families (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4071618A (en) | 1974-09-03 | 1978-01-31 | Research Foundation For Microbial Diseases Of Osaka University | Process for preparing virus disease live vaccines |
JPS57136528A (en) | 1981-02-09 | 1982-08-23 | Hayashibara Biochem Lab Inc | Preparation of viral vaccine |
NZ219515A (en) | 1987-02-10 | 1989-09-27 | Wellcome Found | Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope |
US5854037A (en) | 1989-08-28 | 1998-12-29 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
US6001634A (en) | 1989-08-28 | 1999-12-14 | Palese; Peter | Recombinant negative strand RNA viruses |
US5840520A (en) | 1989-08-28 | 1998-11-24 | Aviron | Recombinant negative strand RNA virus expression systems |
US5786199A (en) | 1989-08-28 | 1998-07-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand RNA virus expression systems and vaccines |
ES2150493T5 (es) | 1993-05-25 | 2004-07-01 | Wyeth Holdings Corporation | Adyuvantes para vacunas contra el virus sincitico respiratorio. |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
JP3484215B2 (ja) | 1994-01-27 | 2004-01-06 | 花王株式会社 | チャイニーズハムスター卵巣細胞変異株 |
PT1820512E (pt) | 1994-05-10 | 2013-10-09 | Boehringer Ingelheim Vetmed | Vacina viva modificada melhorada contra brsv |
US5750394A (en) | 1994-05-20 | 1998-05-12 | The Mount Sinai Medical Center | Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication |
CA2149197A1 (en) | 1994-06-17 | 1995-12-18 | Irene Popiel | Production of an efficacious toxoplasma gondii bradyzoite vaccine in tissue culture |
PT702085E (pt) | 1994-07-18 | 2004-04-30 | Karl Klaus Conzelmann | Virus de arn de cadeia negativa nao segmentada infeccioso recombinante |
EP0700991A1 (en) | 1994-09-12 | 1996-03-13 | Bayer Corporation | Commercial scale concentrated preharvest tissue culture produced live T. Gondii bradyzoite and products and processes |
WO1996010400A1 (en) | 1994-09-30 | 1996-04-11 | The Uab Research Foundation | Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses |
EP0704533A1 (en) | 1994-09-30 | 1996-04-03 | Bayer Ag | An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
US5716821A (en) | 1994-09-30 | 1998-02-10 | Uab Research Foundation | Prevention and treatment of respiratory tract disease |
AU3727895A (en) | 1994-09-30 | 1996-04-26 | St. Jude Children's Research Hospital | Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus |
US6843996B1 (en) | 1995-06-05 | 2005-01-18 | Medimmune Vaccines, Inc. | Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation |
ATE181112T1 (de) | 1995-08-09 | 1999-06-15 | Schweiz Serum & Impfinst | Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren |
US6037348A (en) | 1996-02-09 | 2000-03-14 | Eli Lilly And Company | Inhibition of viral replication |
DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
US5994526A (en) | 1996-06-21 | 1999-11-30 | Plant Genetic Systems | Gene expression in plants |
BR9710363A (pt) | 1996-07-15 | 2000-01-11 | Us Gov Health & Human Serv | "vìrus sincicial respirátorio recombinante infeccioso isolado, partìcula do mesmo, processos para estimular o sistema imunológico de um indivìduo para induzir proteção contra o vìrus sincicial respiratório e para produzir uma partìcula de vìrus sincicial respiratório recombinante, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante composição e ceta de vìrus sincicial respiratório recombinante" |
US6271011B1 (en) | 1996-10-15 | 2001-08-07 | The University Of Georgia Research Foundation, Inc. | Pasteurella neuraminidase coding sequences and diagnostic methods |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
WO1998048834A1 (en) | 1997-04-30 | 1998-11-05 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents |
CA2291216A1 (en) | 1997-05-23 | 1998-11-26 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences |
CA2297786C (en) | 1997-08-05 | 2011-06-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie | New immunoprotective influenza antigen and its use in vaccination |
US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
US20020010143A1 (en) | 1997-09-26 | 2002-01-24 | Miguel S. Barbosa | Compositions and methods for the treatment of human cytomegalovirus infection |
KR100281676B1 (ko) | 1997-11-29 | 2001-04-02 | 신동권 | 신규한독감생백신바이러스 |
US6146642A (en) | 1998-09-14 | 2000-11-14 | Mount Sinai School Of Medicine, Of The City University Of New York | Recombinant new castle disease virus RNA expression systems and vaccines |
US6544785B1 (en) | 1998-09-14 | 2003-04-08 | Mount Sinai School Of Medicine Of New York University | Helper-free rescue of recombinant negative strand RNA viruses |
US6270958B1 (en) | 1998-10-29 | 2001-08-07 | Washington University | Detection of negative-strand RNA viruses |
AU774437B2 (en) | 1999-02-22 | 2004-06-24 | Transgene S.A. | Method for obtaining a purified viral preparation |
EP1035209A1 (en) | 1999-03-06 | 2000-09-13 | ARTEMIS Pharmaceuticals GmbH | Stable recombinant influenza viruses free of helper viruses |
US8715940B2 (en) | 1999-04-06 | 2014-05-06 | Wisconsin Alumni Research Foundation | Method of making recombinant influenza virus |
DK1185615T3 (da) | 1999-04-06 | 2007-11-05 | Wisconsin Alumni Res Found | Rekombinante influenzavirus til vacciner og genterapi |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
ATE353370T1 (de) | 1999-07-14 | 2007-02-15 | Sinai School Medicine | In vitro-rekonstitution von segmentierten, negativstrang-rna-viren |
WO2001025462A1 (en) | 1999-10-01 | 2001-04-12 | Genovo, Incorporated | Production of recombinant aav using adenovirus comprising aav rep/cap genes |
US6686168B1 (en) | 1999-11-04 | 2004-02-03 | Zymogenetics, Inc. | Cell surface display of proteins by recombinant host cells |
US7192759B1 (en) | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
CA2395610A1 (en) | 1999-12-30 | 2001-07-12 | University Of Louisville Research Foundation, Inc. | Methods and compositions for inhibiting adhesion by microorganisms |
ATE473272T1 (de) | 2000-03-03 | 2010-07-15 | Chemo Sero Therapeut Res Inst | In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle |
ATE488577T1 (de) | 2000-04-14 | 2010-12-15 | Wisconsin Alumni Res Found | Mutiertes ionenkanalprotein enthaltende viren |
SI1317559T1 (sl) | 2000-04-28 | 2009-04-30 | St Jude Childrens Res Hospital | Sistem transfekcije dna za pripravo infektivne negativne verige virusne rna |
US6358733B1 (en) | 2000-05-19 | 2002-03-19 | Apolife, Inc. | Expression of heterologous multi-domain proteins in yeast |
US20040241139A1 (en) | 2000-07-20 | 2004-12-02 | Gerd Hobom | Recombinant influenza viruses with bicistronic vRNAs coding for two genes in tandem arrangement |
DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
EP1201760A1 (en) | 2000-10-30 | 2002-05-02 | ARTEMIS Pharmaceuticals GmbH | Influenza virus vector for human dendritic cells |
ES2327719T3 (es) | 2001-01-18 | 2009-11-03 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Complejos de proteina oligomerica recombinante con potencial inmunogenico mejorado. |
EP1233059A1 (en) | 2001-02-09 | 2002-08-21 | ARTEMIS Pharmaceuticals GmbH | Influenza viruses with enhanced transcriptional and replicational capacities |
WO2002068632A2 (en) | 2001-02-23 | 2002-09-06 | Wisconsin Alumni Research Foundation | Methods to identify mutant cells with altered sialic acid |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
US7682618B2 (en) | 2001-11-07 | 2010-03-23 | The United States Of America As Represented By The Secretary Of The Army | Generation of virus-like particles and use as panfilovirus vaccine |
US20040057967A1 (en) | 2001-11-07 | 2004-03-25 | Sina Bavari | Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding |
US6951752B2 (en) | 2001-12-10 | 2005-10-04 | Bexter Healthcare S.A. | Method for large scale production of virus antigen |
US7211378B2 (en) | 2002-01-31 | 2007-05-01 | Wisconsin Alumni Research Foundation | Filovirus vectors and noninfectious filovirus-based particles |
CA2816242C (en) | 2002-02-13 | 2019-01-08 | Wisconsin Alumni Research Foundation | Signal for packaging of influenza virus vectors |
BRPI0307679A2 (pt) | 2002-02-13 | 2016-11-08 | Wisconsin Alumni Res Found | vetor viral de influenza, vírus recombinate de influenza, molécula isolada de ácido nucleico e métodos para expressar um segmento heterólogo de ácido nucleico em uma célula e para preparar vírus semelhante a influenza incompetente na replicação. |
WO2003076462A1 (en) | 2002-03-08 | 2003-09-18 | Crucell Holland B.V. | Use of recombinant trypsin for vaccine production |
FR2837497A1 (fr) | 2002-03-22 | 2003-09-26 | Univ Nantes | Procede de production de vecteurs lentiviraux a haut titre |
DK1499348T3 (en) | 2002-04-26 | 2015-01-05 | Medimmune Llc | PROCEDURE FOR PREPARING INFECTIOUS INFLUENZA B-VIRA IN CELL CULTURE |
US7465456B2 (en) | 2002-04-26 | 2008-12-16 | Medimmune, Llc | Multi plasmid system for the production of influenza virus |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
US20060088909A1 (en) | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
CN101058800B (zh) | 2002-07-09 | 2013-03-13 | 巴克斯特国际有限公司 | 用于细胞培养的无动物蛋白质培养基 |
US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
US20040142322A1 (en) | 2002-10-07 | 2004-07-22 | Schering Corporation | Continuous non-radioactive polymerase assay |
CN1809633B (zh) | 2003-04-23 | 2011-01-19 | 威斯康星旧生研究基金会 | 跨膜蛋白基因中含有突变的重组流感病毒 |
BRPI0410702B1 (pt) | 2003-05-28 | 2022-04-12 | Wisconsin Alumni Research Foundation | Composição, métodos para preparar um vírus de influenza e um veículo de liberação de genes, e, vírus |
WO2005028658A2 (en) | 2003-05-28 | 2005-03-31 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with a polii promoter and ribozymes |
CA2816222A1 (en) | 2003-06-16 | 2005-03-03 | Medimmune Vaccines, Inc. | Influenza hemagglutinin and neuraminidase variants |
US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
US20060240515A1 (en) | 2003-07-21 | 2006-10-26 | Dimitrov Dimiter S | Soluble fragments of the SARS-CoV spike glycoprotein |
US7037707B2 (en) | 2003-09-04 | 2006-05-02 | St. Jude Children's Research Hospital | Method for generating influenza viruses and vaccines |
US7279275B2 (en) | 2003-11-03 | 2007-10-09 | Washington University | Methods and compositions for detection of segmented negative strand RNA viruses |
ATE469972T1 (de) | 2003-12-23 | 2010-06-15 | Medimmune Llc | Multiplasmid-system zur erzeugung des grippevirus |
JP2005245302A (ja) | 2004-03-04 | 2005-09-15 | Kanazawa Univ Tlo Inc | 組換えインフルエンザウイルスおよびそれを用いたワクチン |
WO2006073422A2 (en) | 2004-04-13 | 2006-07-13 | U.S. Army Medical Research Institute Of Infectious Diseases | Activation of natural killer (nk) cells and methods of use |
EP1747268A1 (en) | 2004-05-20 | 2007-01-31 | ID Biomedical Corporation | Process for the production of an influenza vaccine |
AU2005248377B2 (en) | 2004-05-25 | 2011-03-24 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
WO2006027698A1 (en) | 2004-09-09 | 2006-03-16 | Novartis Vaccines And Diagnostics Gmbh & Co Kg. | Decreasing potential iatrogenic risks associated with influenza vaccines |
JP4986859B2 (ja) | 2004-11-11 | 2012-07-25 | アボツト・バイオロジカルズ・ベー・ブイ | 欠陥インフルエンザウイルス粒子 |
US7968101B2 (en) | 2004-11-19 | 2011-06-28 | Wisconsin Alumni Research Foundation | Recombinant influenza vectors with tandem transcription units |
KR101323459B1 (ko) | 2004-12-23 | 2013-10-29 | 메디뮨 엘엘씨 | 바이러스의 증식을 위한 비종양형성성 mdck 세포주 |
BRPI0518568A2 (pt) | 2004-12-24 | 2008-11-25 | Solvay Pharm Bv | mÉtodo para produzir uma partÍcula do vÍrus da influenza replicativo sem o uso de vÍrus auxiliar, partÍcula de vÍrus da influenza replicativo, cÉlula, composiÇço, uso de uma composiÇço, mÉtodo para gerar proteÇço imunolàgica contra infecÇço de um indivÍduo com um vÍrus da influenza, e, Ácido nuclÉico |
CA2600730C (en) | 2005-03-08 | 2014-11-25 | Medimmune, Inc. | Influenza hemagglutinin and neuraminidase variants |
EP1877088B1 (en) | 2005-04-11 | 2014-12-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine against pandemic strains of influenza viruses |
EP2614836A3 (en) | 2005-10-17 | 2013-10-23 | MedImmune, LLC | High growth reassortant influenza A virus |
HUE026136T2 (en) | 2005-10-18 | 2016-05-30 | Novavax Inc | Functional influenza virus-like particles (VLP-K) |
JP2009514850A (ja) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン |
KR20110110853A (ko) | 2006-01-27 | 2011-10-07 | 노파르티스 파르마 아게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
JP2007259758A (ja) | 2006-03-28 | 2007-10-11 | Wisconsin Alumni Research Foundation | H3型ウマa型インフルエンザウイルス |
AU2014202470B2 (en) | 2006-03-31 | 2016-08-04 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
AU2007245192B2 (en) | 2006-03-31 | 2012-04-12 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
AU2012204138B2 (en) | 2006-03-31 | 2014-02-06 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
EP2022849A4 (en) | 2006-05-11 | 2010-10-06 | Chemo Sero Therapeut Res Inst | METHOD FOR PROLIFERATION OF INFLUENZA VIRUS |
WO2007146057A2 (en) | 2006-06-09 | 2007-12-21 | Wisconsin Alumni Research Foundation | Screening method for modulators of viral transcription or replication |
KR20090016704A (ko) | 2006-06-15 | 2009-02-17 | 노파르티스 아게 | 보조제-보존 수회-투여 인플루엔자 접종 요법 |
US7507411B2 (en) | 2006-06-23 | 2009-03-24 | University Of Saskatchewan | Attenuated influenza NS1 variants |
WO2008133701A1 (en) | 2006-07-21 | 2008-11-06 | Medimmune, Llc. | Methods and compositions for increasing replication capacity of an influenza virus |
KR101586968B1 (ko) | 2006-08-09 | 2016-01-20 | 메디뮨 엘엘씨 | 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체 |
SG174813A1 (en) | 2006-09-15 | 2011-10-28 | Medimmune Llc | Mdck cell lines supporting viral growth to high titers and bioreactor process using the same |
PL2121011T3 (pl) | 2006-12-06 | 2014-10-31 | Novartis Ag | Szczepionki zawierające antygeny czterech szczepów wirusa grypy |
US8465960B2 (en) | 2007-03-28 | 2013-06-18 | Wisconsin Alumni Research Foundation | Influenza B viruses with reduced sensitivity to neuraminidase inhibitors |
TR201901624T4 (tr) | 2007-04-16 | 2019-02-21 | Bae Systems Plc | Aşınma sensörleri. |
US8597661B2 (en) | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
US8043856B2 (en) | 2007-06-14 | 2011-10-25 | Wisconsin Alumni Research Foundation | Adenoviral vectors for influenza virus production |
US8673613B2 (en) | 2007-06-18 | 2014-03-18 | Medimmune, Llc | Influenza B viruses having alterations in the hemaglutinin polypeptide |
US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
EP2048237A1 (en) | 2007-10-05 | 2009-04-15 | Avir Green Hills Biotechnology Research Development Trade Ag | Replication deficient Influenza virus for the expression of heterologous sequences |
EA201070066A1 (ru) | 2007-06-27 | 2010-06-30 | Новартис Аг | Вакцины против гриппа с низким содержанием добавок |
WO2009014919A2 (en) | 2007-07-13 | 2009-01-29 | Iowa State University Research Foundation, Inc. | H2n3 influenza a viruses and methods of use |
US9593340B2 (en) | 2007-10-15 | 2017-03-14 | Admedus Vaccines Pty Ltd. | Expression system for modulating an immune response |
WO2009128867A2 (en) | 2008-01-07 | 2009-10-22 | Warf - Wisconsin Alumni Research Foundation | Recombinant biologically contained filovirus |
WO2010006144A2 (en) | 2008-07-11 | 2010-01-14 | Medlmmune, Llc. | Influenza hemagglutinin and neuraminidase variants |
SG2013057732A (en) | 2008-08-08 | 2015-02-27 | Ligocyte Pharmaceuticals Inc | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
US9222118B2 (en) | 2008-11-07 | 2015-12-29 | Wisconsin Alumni Research Foundation | Screen for inhibitors of filovirus and uses therefor |
CN101613678A (zh) * | 2009-01-14 | 2009-12-30 | 中国农业科学院哈尔滨兽医研究所 | 稳定表达β-半乳糖苷α-2,3-唾液酸转移酶I(ST3GAL I)的MDCK细胞系的建立 |
SG177655A1 (en) | 2009-07-16 | 2012-02-28 | Crucell Holland Bv | Production of polio virus at high titers for vaccine production |
US8828406B2 (en) | 2009-07-30 | 2014-09-09 | Icahn School Of Medicine At Mount Sinai | Influenza viruses and uses thereof |
US8507247B2 (en) | 2009-08-11 | 2013-08-13 | Wisconsin Alumni Research Foundation | Influenza A virus with attenuating mutations in NS2 protein |
ES2813347T3 (es) | 2009-10-26 | 2021-03-23 | Wisconsin Alumni Res Found | Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
EP2599863B1 (en) | 2009-11-20 | 2017-08-02 | Danisco US Inc. | Beta-glucosidase variants with improved properties |
WO2011087839A1 (en) | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
US20140004149A1 (en) | 2010-01-24 | 2014-01-02 | Biological Mimetics, Inc. | Immunogenic Influenza Composition |
US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
EP2555795B1 (en) | 2010-04-09 | 2016-07-13 | Universiteit Utrecht Holding B.V. | Recombinant multimeric influenza proteins |
US9526777B2 (en) | 2010-04-16 | 2016-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein |
GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
WO2012033236A1 (ko) | 2010-09-06 | 2012-03-15 | 에스케이케미칼 주식회사 | 무혈청 배양 및 부유 배양에 적응된 mdck 세포주 및 상기 세포를 사용하여 백신용 바이러스를 제조하는 방법 |
WO2012045882A2 (en) | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
EP2652496B1 (en) | 2010-12-13 | 2018-01-17 | The University of Utah Research Foundation | Vaccine antigens that direct immunity to conserved epitopes |
US9284533B2 (en) | 2011-06-24 | 2016-03-15 | Flugen, Inc. | Influenza virus mutants and uses therefor |
WO2013032942A1 (en) | 2011-08-26 | 2013-03-07 | Yoshihiro Kawaoka | Influenza viruses with mutant pb2 gene segment as live attenuated vaccines |
CN102304495A (zh) | 2011-09-08 | 2012-01-04 | 中国农业科学院上海兽医研究所 | 高效表达ha蛋白的重组流感病毒及其制备方法和应用 |
JP2015501141A (ja) | 2011-10-07 | 2015-01-15 | メディミューン,エルエルシー | インフルエンザヘマグルチニン変異体 |
WO2013087945A2 (en) | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
US9506041B2 (en) | 2012-03-26 | 2016-11-29 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Delivery of packaged RNA to mammalian cells |
US20160287692A1 (en) | 2012-11-16 | 2016-10-06 | Medimmune, Llc | Swine influenza hemagglutinin and neuraminidase variants |
EP2970452A2 (en) | 2013-03-15 | 2016-01-20 | AC Immune S.A. | Anti-tau antibodies and methods of use |
WO2014195920A2 (en) | 2013-06-06 | 2014-12-11 | Novartis Ag | Influenza virus reassortment |
EP3022296B1 (en) | 2013-07-15 | 2022-12-28 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
US9757446B2 (en) | 2014-03-17 | 2017-09-12 | Flugen, Inc. | Influenza virus vectors and uses therefor |
WO2015196150A2 (en) | 2014-06-20 | 2015-12-23 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10576141B2 (en) | 2014-09-03 | 2020-03-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use |
AU2015327819B2 (en) | 2014-10-03 | 2021-07-01 | Massachusetts Institute Of Technology | Antibodies that bind ebola glycoprotein and uses thereof |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
US10429386B2 (en) | 2015-03-10 | 2019-10-01 | The Regents Of The University Of California | Antibodies to the surface of Toxoplasma gondii oocysts and methods of use thereof |
US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
JP2018524323A (ja) | 2015-06-26 | 2018-08-30 | セキラス ユーケー リミテッド | 抗原がマッチしたインフルエンザワクチン |
US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
US20170121391A1 (en) | 2015-07-07 | 2017-05-04 | Wisconsin Alumni Research Foundation (Warf) | Potent glycoprotein antibody as a therapeutic against ebola virus |
US10494613B2 (en) | 2015-08-28 | 2019-12-03 | Wisconsin Alumni Research Foundation (Warf) | Generation of infectious influenza viruses from virus-like particles |
CN105296356A (zh) | 2015-12-02 | 2016-02-03 | 河南农业大学 | 一种刚地弓形虫卵囊的制备、纯化及保存方法 |
US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
EP3417056A1 (en) | 2016-02-19 | 2018-12-26 | Wisconsin Alumni Research Foundation (WARF) | Improved influenza b virus replication for vaccine development |
JP2018064493A (ja) | 2016-10-19 | 2018-04-26 | 京都府公立大学法人 | Mdck細胞を用いたインフルエンザウイルスの増殖方法 |
US11197926B2 (en) | 2017-10-25 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
WO2019241579A1 (en) | 2018-06-13 | 2019-12-19 | Wisconsin Alumni Research Foundation | Toxoplasma gondii vaccine |
JP2021533157A (ja) | 2018-08-07 | 2021-12-02 | ウィスコンシン アルムニ リサーチ ファンデイション | 組換えの生物学的に封じ込められたフィロウイルスワクチン |
US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
WO2020167432A2 (en) | 2019-01-23 | 2020-08-20 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
CN113874496A (zh) | 2019-02-08 | 2021-12-31 | 威斯康星校友研究基金会(Warf) | 人源化细胞系 |
US11390649B2 (en) | 2019-05-01 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
WO2020264141A1 (en) | 2019-06-26 | 2020-12-30 | Icahn School Of Medicine At Mount Sinai | Influenza virus neuraminidase and uses thereof |
EP4022046A2 (en) | 2019-08-27 | 2022-07-06 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized ha for replication in eggs |
EP4093415A1 (en) | 2020-01-24 | 2022-11-30 | Wisconsin Alumni Research Foundation (WARF) | Recombinant influenza viruses with stabilized na |
US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
WO2021242597A1 (en) | 2020-05-23 | 2021-12-02 | Wisconsin Alumni Research Foundation ("Warf") | Ace2 expressing influenza virus |
-
2020
- 2020-02-07 CN CN202080025289.6A patent/CN113874496A/zh active Pending
- 2020-02-07 JP JP2021546853A patent/JP2022522112A/ja active Pending
- 2020-02-07 WO PCT/US2020/017342 patent/WO2020163804A1/en unknown
- 2020-02-07 EP EP20714015.3A patent/EP3921413A1/en active Pending
- 2020-02-07 US US16/785,449 patent/US11851648B2/en active Active
-
2023
- 2023-11-30 US US18/525,460 patent/US20240318167A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100021499A1 (en) * | 2008-06-11 | 2010-01-28 | Flugen, Inc. | Cell-based systems for producing influenza vaccines |
US20130243744A1 (en) * | 2011-01-06 | 2013-09-19 | Michael J. Betenbaugh | Method of production of recombinant glycoproteins with increased circulatory half-life in mammalian cells |
JP2017506903A (ja) * | 2014-03-04 | 2017-03-16 | シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC | ウイルス耐性細胞及びその使用 |
Non-Patent Citations (1)
Title |
---|
MIKHALI MATROSOVICH ET AL., JOURNAL OF VIROLOGY, vol. Vo. 77, No. 15, JPN6023014689, August 2003 (2003-08-01), pages 8418 - 8425, ISSN: 0005139145 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12076387B2 (en) | 2010-03-23 | 2024-09-03 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
US11802273B2 (en) | 2014-06-20 | 2023-10-31 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US11851648B2 (en) | 2019-02-08 | 2023-12-26 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
US12122807B2 (en) | 2022-07-18 | 2024-10-22 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
Also Published As
Publication number | Publication date |
---|---|
EP3921413A1 (en) | 2021-12-15 |
WO2020163804A1 (en) | 2020-08-13 |
CN113874496A (zh) | 2021-12-31 |
US11851648B2 (en) | 2023-12-26 |
US20200291384A1 (en) | 2020-09-17 |
US20240318167A1 (en) | 2024-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7083364B2 (ja) | 配列操作のための最適化されたCRISPR-Cas二重ニッカーゼ系、方法および組成物 | |
JP2022522112A (ja) | ヒト化細胞系 | |
JP2024138266A (ja) | 新規Cas12b酵素およびシステム | |
KR20210139265A (ko) | 표적 서열에서 핵염기를 변형하기 위한 아데노신 데아미나제 염기 편집기 및 이의 사용 방법 | |
JP5320546B2 (ja) | Tol1因子のトランスポザーゼ及びそれを用いたDNA導入システム | |
KR20200097760A (ko) | 유전자 편집을 위한 cpf1-관련 방법 및 조성물 | |
KR20210077732A (ko) | Nme2cas9-데아미나아제 융합 단백질에 의한 프로그램 가능한 dna 염기 편집 | |
JP2019520391A (ja) | 網膜変性を処置するためのcrispr/cas9ベースの組成物および方法 | |
CN113906138A (zh) | 将沉默活性引入多个功能性失调的rna分子并修饰其对一感兴趣的基因的特异性 | |
WO2018227755A1 (zh) | 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其应用 | |
KR20210124280A (ko) | 표적-이탈 탈아미노화가 감소된 핵염기 편집기 및 이를 이용하여 핵염기 표적 서열을 변형시키는 방법 | |
CN110234762A (zh) | 用于治疗肌强直性营养不良的组合物和方法 | |
KR20220062289A (ko) | Rna-가이드된 뉴클레아제 및 그의 활성 단편 및 변이체 및 사용 방법 | |
US11492614B2 (en) | Stem loop RNA mediated transport of mitochondria genome editing molecules (endonucleases) into the mitochondria | |
Hirai et al. | Role of mouse hepatitis virus (MHV) receptor murine CEACAM1 in the resistance of mice to MHV infection: studies of mice with chimeric mCEACAM1a and mCEACAM1b | |
CN114174520A (zh) | 用于选择性基因调节的组合物和方法 | |
CN114502731A (zh) | 基于转座子的免疫细胞的修饰 | |
JP2023113657A (ja) | B4galt1バリアント及びその使用 | |
Chen et al. | Intronic deletions of tva receptor gene decrease the susceptibility to infection by avian sarcoma and leukosis virus subgroup A | |
WO2005003342A1 (ja) | メチル化を利用したトランスジェニック生物を作製する方法およびシステム | |
KR20220033468A (ko) | 강화된 이종이식편 생존 및/또는 내성을 위한 하나 이상의 변형된 유전자를 갖는 세포, 조직, 장기 및/또는 동물 | |
WO2024179232A1 (zh) | 激活异染色质基因的方法及应用 | |
US20160304854A1 (en) | Mitochondrial genome editing | |
Chen et al. | A premature stop codon within the tvb receptor gene results in decreased susceptibility to infection by avian leukosis virus subgroups B, D, and E | |
Michalski et al. | Generation of a new frizzled 2 flox mouse model to clarify its role in development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220328 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220408 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220412 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220510 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220526 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230418 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240229 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240906 |